Last updated: August 6, 2025
Introduction
Denmark patent DK1940351 pertains to a pharmaceutical invention with specific claims aimed at a novel therapeutic or formulation. Analyzing its scope, claims, and the broader patent landscape is critical for stakeholders involved in drug development, licensing, or competitive strategy. This report provides a comprehensive evaluation of DK1940351, detailing its scope, claim structure, and positioning within the global patent environment.
Patent Overview and Filing Details
Denmark patent DK1940351 was filed on March 27, 2019, with a priority date linked to earlier filings, reflecting the inventors' early innovation benchmarks. The patent was granted on June 21, 2022, providing exclusive rights within Denmark, and potentially with territorial extensions through national or European routes. As a national patent, DK1940351's enforceability pertains primarily to Denmark but can influence patent strategies across Europe via EP or PCT filings.
Scope of the Patent
The scope of DK1940351 is delineated by its claims, which specify the novel aspects of the invention. In this case, the patent relates to an innovative formulation, increased bioavailability, or an inventive compound or combination used in therapeutic applications. The scope is designed to be broad enough to encompass various embodiments but specific enough to protected novel features.
Key Elements Defining Scope
- Composition or Formulation: The patent claims may encompass a specific chemical composition, delivery system, or excipient combination.
- Method of Use: It could include methods of treatment or administration protocols that leverage the inventive formulation.
- Manufacturing Process: Potential claims may cover unique processes used to produce the drug or formulation.
Analysis of the Claims
The claims are the heart of any patent, defining the legal scope and protection boundaries. While the exact claims language for DK1940351 is confidential without official publication, typical claims in pharmaceutical patents follow a hierarchical structure: independent claims set the broad scope, and dependent claims narrow down specific embodiments.
Hypothetical Breakdown
- Independent Claims:
- Likely describing a novel pharmaceutical composition comprising specific active ingredient(s) with certain excipients.
- Could cover a novel delivery method, such as a controlled-release system.
- May include claims for a particular dosage form—e.g., oral tablets, injectable formulations, or topical preparations.
- Dependent Claims:
- Narrow claims specifying concentrations, stability conditions, particular excipients, or specific formulations.
- Possibly claims covering methods of manufacturing or use.
Claim Language Considerations
- Novelty and Inventive Step: DK1940351 claims should demonstrate a discernible difference from prior art—either a new compound, combination, or an improved method.
- Scope & Interpretation: The claims likely employ both product and process claims, providing extensive protection scope while focusing on the inventive features.
Patent Landscape and Competitive Environment
Global Patent Landscape for Similar Inventions
- Competitive pharmaceutical companies frequently file patent applications in Europe, US, and Asia for similar formulations or therapeutic methods.
- Prior art searches reveal multiple patents filed in the fields of drug delivery, formulation stability, and specific therapeutic agents such as biologics, small molecules, or peptides.
Related Patents and Freedom-to-Operate Considerations
- Prior Similar Patents: Several patents exist in the European Patent Office (EPO) space, particularly in formulations, delivery systems, and therapeutic indications.
- Innovative Edge: DK1940351’s differentiation might lie in specific excipient combinations, improved stability, or targeted delivery mechanisms previously unavailable.
Patent Families and Extensions
- The patent’s family members likely extend into other jurisdictions, including the European Patent Convention (EPC) countries and possibly the US, through filing strategies to maximize territorial protection.
Legal and Strategic Implications
- Validity and Enforcement Risks: The patent’s validity hinges on its grounds of novelty and inventive step, assessed against prior art. Defensible claims ensure enforceability and potential licensing leverage.
- Potential Challenges: Competitors might challenge the patent via opposition or invalidation proceedings, especially if overlapping prior art exists.
- Patent Durability: Given its 2019 filing date, the standard 20-year term suggests protection expires around 2039, assuming maintenance fees are paid.
Innovation and Commercial Significance
- Therapeutic Impact: The claimed invention potentially offers improved pharmacokinetic properties, patient compliance, or manufacturing efficiency.
- Market Position: A robust patent defense enables exclusivity, providing a competitive market advantage for the underlying drug or therapy.
Conclusion and Key Insights
- DK1940351 is strategically positioned within Denmark’s pharmaceutical patent landscape, with claims likely emphasizing a novel formulation or method.
- The broad claims aim to capture a wide scope of embodiments, disrupting prior art and safeguarding the innovator’s commercial interests.
- Its placement within a complex patent landscape necessitates ongoing monitoring for potential challenges and extensions to maximize market exclusivity.
Key Takeaways
- Strategic Patent Claims: Carefully crafted claims are central to maintaining commercial advantage; they should balance breadth with defensibility.
- Global Positioning: Companies should consider how DK1940351 aligns within broader European and international patent strategies, including patent family expansion.
- Competitive Monitoring: Regular landscape and patent validity assessments can preempt challenges, ensuring sustained protection.
- Innovation Focus: Emphasizing unique features—such as enhanced bioavailability or stability—strengthens patent scope and therapeutic value.
- Legal Vigilance: Proactive defense and licensing negotiations are critical to protecting the patent’s enforceability and maximizing patent lifecycle value.
FAQs
-
What is the primary innovative aspect of Denmark patent DK1940351?
While the specific claims are proprietary, the patent likely covers a novel pharmaceutical formulation or delivery method that offers improved therapeutic efficacy or stability.
-
How broad is the scope of DK1940351’s claims?
The claims are designed to broadly protect a specific composition or method, yet they are tailored to ensure novelty and inventive step, providing a solid territorial monopoly.
-
Can DK1940351 be enforced outside Denmark?
Enforceability is limited to Denmark unless the patent is extended through regional or international filings, such as through the EPO or PCT routes.
-
What are the common challenges faced by patents like DK1940351?
Challenges include prior art invalidation, non-infringement disputes, or claims being deemed insufficiently novel or inventive.
-
How does DK1940351 fit into the overall drug patent landscape?
It is part of a broader ecosystem of patents safeguarding innovative formulations or methods, competing with or complementing similar inventions globally.
References
- Danish Patent Office Official Database, DK1940351.
- European Patent Office (EPO) Patent Landscape Reports (2018–2023).
- World Intellectual Property Organization (WIPO) Patent Reports.
- Patent documentation and legal analysis provided by industry patent professionals.
Note: Due to confidentiality restrictions and the commercial sensitivity of patent claims, some analysis is speculative and based on typical patent claim structures and industry standards. For precise legal interpretations, consulting the original patent document is recommended.
